Photo for representational purpose only. Reuters file
December 23
A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.
After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus’s Delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca. Reuters
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
Heat wave: Punjab announces early summer holidays for government, private schools from May 21
Teaching/non-teaching staff would continue to perform their ...
Iranian President Ebrahim Raisi, Foreign Minister Hossein die in helicopter crash
Vice-president, state TV confirm deaths of all aboard Presid...
‘Deeply saddened and shocked’: India condoles Iranian President Raisi and Foreign Minister's death in helicopter crash
The helicopter crashed in the northwest of Iran on Sunday
Will unusual heatwave in Himachal break Shimla’s highest-ever temperature record of 32.4°C in May this year? Here's what weatherman says
Mercury continues to soar in Himachal, MeT sounds yellow ale...
